Allergan has struck a deal to acquire the floundering Repros Therapeutics. The bargain-basement takeout gives Allergan the rights to a uterine fibroid drug that is on the cusp of phase 3, but also responsibility for compiling the large safety database the FDA wants to see before signing off on further development.
Repros began the year looking to build on phase 2 data showing progesterone receptor blocker Proellex stops menstruation and reduces fibroid size. But the wheels quickly came off after the company failed to alleviate the FDA’s concerns about the drug’s effect on the liver, resulting in the partial clinical hold dragging on for longer than hoped.
The situation went from bad to worse in July when the FDA said only a large safety database will persuade it to clear Proellex for further development. With Repros deep in penny-stock territory after years of struggles and its cash reserves down to $1.8 million, that looked beyond the biotech.
Now though, Allergan has dug out some loose change to rescue the program. Repros had a market cap of less than $19 million before news of the takeover broke. Allergan sealed the deal with a $0.67-a-share bid, a 43% premium over Repros’ closing price yesterday.
For that relatively small sum and the cost of the safety study, Allergan could gain a phase 3-ready uterine fibroid drug to sit alongside its existing approved product in the indication, Esmya. Or the company may simply prove that Proellex is beyond saving.
Allergan is taking on the challenge of answering that question at the same time as regulators in Europe are pressuring it to show Esmya has a favorable risk-benefit profile. Liver effects are behind Esmya’s problems, too.
Repros is also developing Proellex for use in endometriosis and has a treatment for hypogonadotropic hypogonadism, estrogen receptor antagonist enclomiphene, in the clinic.
By Nick Paul Taylor
Source: Fierce Biotech
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).
